Indian Drug Makers Increase Nutraceutical Activity
This article was originally published in PharmAsia News
Several Indian drug makers are expanding their nutraceutical products to take advantage of an expected explosion in the market. The pharmaceutical industry estimates the nutraceutical segment of medicine to be worth about $400 million in India, a major part of a $7 billion health care sector. An Ernst & Young partner questioned, however, whether the segment also should include ayurvedic and herbal products, which in India are considered drugs for regulatory purposes. Those products are expected to reach $190 billion in sales by 2010. Among drug makers seeking to expand are Elder Pharma, Glenmark, Plethico, Troikaa and Wockhardt. (Click here for more
You may also be interested in...
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.